<DOC>
	<DOCNO>NCT01367600</DOCNO>
	<brief_summary>This study open-label extension allow patient complete Protocol MNTX 301 continue receive SC MNTX .</brief_summary>
	<brief_title>Open-Label Treatment Extension Protocol MNTX 301</brief_title>
	<detailed_description />
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1 . Completion protocol MNTX 301 ; DoubleBlind Treatment OpenLabel Treatment 2 . Negative pregnancy test 1 . Women pregnant and/or nursing 2 . Any concurrent experimental drug therapy 3 . Evidence fecal impaction 4 . Clinically significant active diverticular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Advanced medical illness</keyword>
</DOC>